{"entity":{"id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Relatlimab + nivolumab, Pembrolizumab in melanoma, run by Krystal Biotech, Inc., now recruiting.","summary":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05970497 by Krystal Biotech, Inc., with 240 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-07. Interventions recorded: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab). Conditions listed: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05970497","url":"https://clinicaltrials.gov/study/NCT05970497"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["relatlimab-nivolumab","pembrolizumab"],"companies":["krystal-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05970497","phase":"1/2","setting":"A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Krystal Biotech, Inc.","enrolled":240,"outcomes":[]},"route":"/trials/nct05970497/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/"}],"company":[{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/"}]}}